Escherichia coli is the most researched microbial organism in the world. Its varied impact on
human health, consisting of commensalism, gastrointestinal disease, or extraintestinal …

Background: Antimicrobial resistance is a serious public-health problem throughout the
world. Escherichia coli, the most common Gram-negative microorganism, has developed …

The increasing emergence and dissemination of multidrug resistant (MDR) bacterial
pathogens accelerate the desires for new antibiotics. Natural products dominate the …

Tigecycline is a last-resort antibiotic that is used to treat severe infections caused by
extensively drug-resistant bacteria. tet (X) has been shown to encode a flavin-dependent …

Antibiotic resistance tends to carry fitness costs, making it difficult to understand how
resistance can be maintained in the absence of continual antibiotic exposure. Here we …

The emergence and rapid spread of methicillin-resistant Staphylococcus aureus (MRSA)
critically requires alternative therapeutic options. New antibacterial drugs and strategies are …

Colistin drug resistance is an emerging public health threat worldwide. The adaptability,
existence and spread of colistin drug resistance in multiple reservoirs and ecological …

Polymyxins, especially polymyxin B and polymyxin E (colistin), are considered to be the last
line of defence against infections caused by multi-drug-resistant (MDR) gram-negative …

Background Since its discovery in 2015, the mobile colistin resistance gene mcr-1 has been
reported in bacteria from> 50 countries. Although aquaculture-associated bacteria may act …

Treatment of multi-drug resistant (MDR) Escherichia coli intestinal infections are being
hampered by the presence of the mcr-1 (colistin) and tet (tetracycline) resistance genes in …